MX2023002396A - Métodos para tratar el deterioro cognitivo relacionado con la edad. - Google Patents
Métodos para tratar el deterioro cognitivo relacionado con la edad.Info
- Publication number
- MX2023002396A MX2023002396A MX2023002396A MX2023002396A MX2023002396A MX 2023002396 A MX2023002396 A MX 2023002396A MX 2023002396 A MX2023002396 A MX 2023002396A MX 2023002396 A MX2023002396 A MX 2023002396A MX 2023002396 A MX2023002396 A MX 2023002396A
- Authority
- MX
- Mexico
- Prior art keywords
- cognitive decline
- age
- methods
- improving
- related cognitive
- Prior art date
Links
- 230000007000 age related cognitive decline Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000003590 rho kinase inhibitor Substances 0.000 abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 241001112258 Moca Species 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000006999 cognitive decline Effects 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical group C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002435 fasudil Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan métodos para tratar sujetos con deterioro cognitivo relacionado con la edad con un inhibidor de la quinasa rho. En una forma de realización preferida, el inhibidor de la quinasa rho es fasudilo, y se administra por vía oral en una dosis diaria de entre 30 y 60 mg por día. Los sujetos tienen un deterioro cognitivo en una escala cognitiva global, como la MoCA o el MMSE, y/o deterioros específicos relacionados con diferentes dominios cognitivos. Un método para reducir la tasa de deterioro cognitivo relacionado con la edad, que comprende administrar a un sujeto con evidencia de deterioro cognitivo relacionado con la edad una cantidad eficaz de un inhibidor de la quinasa rho. Los métodos inventivos ralentizan la tasa de deterioro cognitivo y/o mejoran la cognición con respecto al valor inicial en individuos tratados. Los métodos pueden mejorar la velocidad de procesamiento, aumentar la atención, mejorar la memoria, mejorar el lenguaje, mejorar las capacidades de construcción visual y/o mejorar la función ejecutiva en sujetos que padecen deterioro cognitivo relacionado con la edad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071504P | 2020-08-28 | 2020-08-28 | |
| PCT/US2021/012628 WO2022046160A1 (en) | 2020-08-28 | 2021-01-08 | Methods of treating age-related cognitive decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002396A true MX2023002396A (es) | 2023-05-10 |
Family
ID=80353816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002396A MX2023002396A (es) | 2020-08-28 | 2021-01-08 | Métodos para tratar el deterioro cognitivo relacionado con la edad. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230310447A1 (es) |
| EP (1) | EP4203961A1 (es) |
| CA (1) | CA3188718A1 (es) |
| MX (1) | MX2023002396A (es) |
| WO (1) | WO2022046160A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197823A1 (en) * | 2006-05-09 | 2009-08-06 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
| AU2007281701A1 (en) * | 2006-08-10 | 2008-02-14 | Translational Genomics Research Institute | Compounds for improving learning and memory |
| EP3160590B1 (en) * | 2014-06-30 | 2018-04-25 | Mitochondrial Substrate Invention Limited | Nutrients solutions for enhancement of cognitive function |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
-
2021
- 2021-01-08 MX MX2023002396A patent/MX2023002396A/es unknown
- 2021-01-08 WO PCT/US2021/012628 patent/WO2022046160A1/en unknown
- 2021-01-08 EP EP21862244.7A patent/EP4203961A1/en active Pending
- 2021-01-08 CA CA3188718A patent/CA3188718A1/en active Pending
- 2021-01-08 US US18/043,077 patent/US20230310447A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022046160A1 (en) | 2022-03-03 |
| US20230310447A1 (en) | 2023-10-05 |
| EP4203961A1 (en) | 2023-07-05 |
| CA3188718A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pulvermüller et al. | Therapy-related reorganization of language in both hemispheres of patients with chronic aphasia | |
| Ferrari | The biopsychosocial model—a tool for rheumatologists | |
| MX2022012957A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. | |
| Scurry et al. | Aging impairs temporal sensitivity, but not perceptual synchrony, across modalities | |
| MX2023002396A (es) | Métodos para tratar el deterioro cognitivo relacionado con la edad. | |
| MX2023002165A (es) | Metodos para tratar el deterioro cognitivo relacionado con la edad. | |
| Chitiyo | Special education in Zimbabwe: Issues and trends. | |
| De Luca et al. | Should individuals with chronic aphasia be treated with dedicated PC-based training? Considerations about a case study | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| Akuchekian et al. | Effect of the holy month of Ramadan on coping strategies | |
| Kavian et al. | A Single–subject Study to Examine the Effects of Constrained–induced Aphasia Therapy on Naming Deficit | |
| Hashemian et al. | Effectiveness of neuro-feedback on mathematics disorder | |
| Hwang et al. | The effects of cognitive rehabilitation on Alzheimer’s dementia patients’ cognitive assessment reference diagnosis system performance based on level of cognitive functioning | |
| Gangmei et al. | A Study to Assess the Effectiveness of Pranic Healing Therapy on Backache among Adults At Pranic Healing Centre in Pune City. | |
| Sandyk | Brief communication: electromagnetic fields improve visuospatial performance and reverse agraphia in a parkinsonian patient | |
| McKay et al. | Information processing and cognitive behavior therapy for obsessive-compulsive disorder: Comorbidity of delusions, overvalued ideas, and schizophrenia | |
| Rozaq et al. | The Effect of Speech Therapy With Hijaiyyah Letters on the Capability of Verbal Communication of Stroke Patients | |
| Lee et al. | A Study on the Combined Effect of Cognitive Therapy and Speech Therapy for Aphasics: Comparison of Follow-up Evaluation After Post-Treatment | |
| Krasteva-Ruseva | Use of Spinal Traction in the Complex Treatment of Lumbar Disc Disease | |
| Reilly | Semantic Memory and Language Processing in Aphasia and Dementia | |
| el‐Azhary | One of the best treatments for alopecia areata remains unpublished. | |
| Suess et al. | Cortical tracking of unheard formant modulations derived from silently presented lip movements and its decline with age | |
| González Ponce et al. | The Protection Motivation Theory as a Predictor of the Use of Protective Behavioral Strategies among Young Adults | |
| Seven et al. | AB1374-HPR THE EFFECTIVENESS OF BIOPSYCHOSOCIAL EXERCISE PROGRAM ON PAIN COPING IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND FIBROMYALGIA | |
| Kelly | What constitutes a" new use" of a known composition and should a patentee's purported objective make any difference? |